Consolidated Condensed Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Cash flows from operating activities:
Net loss	$ (3,799,240)	$ (4,315,987)	$ (12,438,742)	$ (16,780,702)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	0	1,272	0	6,230
Changes in operating assets and liabilities:
Prepaid expenses and other			(135,978)	374,916
Research and development supplies			199,446	358,189
Accounts payable			545,150	(93,488)
Other current liabilities			(497,615)	(918,427)
Net cash used in operating activities			(11,212,938)	(14,053,136)
Cash flows from investing activities:
Disposals of property and equipment			0	1,167
Reductions to intellectual property			0	773,478
Net cash provided by investing activities			0	774,645
Cash flows from financing activities:
Net proceeds from issuances of common stock, pre-funded warrants, and warrants			10,714,593	8,029,143
Net cash provided by financing activities			10,714,593	8,029,143
Net decrease in cash and cash equivalents			(498,345)	(5,249,348)
Cash and cash equivalents, beginning of period			1,601,660	6,737,629
Cash and cash equivalents, end of period	1,103,315	1,488,281	1,103,315	1,488,281
Supplemental schedule of non-cash investing and financing activities:
Deemed dividend related to warrant modification	0	$ 0	0	(277,119)
Excluding ELOC Purchase Agreement [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation			659,252	3,000,146
The 2025 ELOC Facility [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation			455,549	$ 0
Cash flows from financing activities:
Net proceeds from issuances of common stock, pre-funded warrants, and warrants	$ 2,943,745		$ 3,818,631